227 related articles for article (PubMed ID: 33958272)
1. Liposome-paclitaxel and carboplatin combination chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma.
Zeng J; Cui X; Cheng L; Chen Y; Du X; Sheng L
Cancer Radiother; 2021 Jul; 25(5):441-446. PubMed ID: 33958272
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.
Chen G; Sheng L; Du X
Cancer Chemother Pharmacol; 2018 Sep; 82(3):505-510. PubMed ID: 29987370
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
[TBL] [Abstract][Full Text] [Related]
4. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
[TBL] [Abstract][Full Text] [Related]
7. Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis.
Yi Q; Liu C; Cui Y; Yang Y; Li Y; Fan X; Wu K
Cancer Med; 2023 Mar; 12(6):6477-6487. PubMed ID: 37012831
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Liu Q; Zhang JH; Deng JY; Ai TS; Zhu HT; Badakhshi H; Zhao KL
Int J Clin Oncol; 2018 Jun; 23(3):458-465. PubMed ID: 29435872
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
[TBL] [Abstract][Full Text] [Related]
11. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers.
Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M
Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma.
Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS
Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
[TBL] [Abstract][Full Text] [Related]
15. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
[TBL] [Abstract][Full Text] [Related]
16. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
[TBL] [Abstract][Full Text] [Related]
17. Definitive concurrent chemoradiotherapy with paclitaxel plus carboplatin is superior to cisplatin plus 5-fluorouracil in patients with inoperable esophageal squamous cell carcinoma using retrospective, real-world evidence.
Hsieh JC; Chiang PC; Hung TM; Chao YK; Kuo YC; Wen CT; Su PJ; Peng MT; Chen HW; Liu HL; Chang HK; Wu MH; Wang HM
Cancer Med; 2021 Dec; 10(23):8300-8309. PubMed ID: 34706159
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
19. A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma.
Xia X; Liu Z; Cai B; Di X; Sun X; Ge X
Cancer Radiother; 2021 Feb; 25(1):39-44. PubMed ID: 33419607
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]